PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Demonstrating Value Created by In-Silico Solutions to Help Maximise Virtual Screening Opportunities - Frost & Sullivan finds that Virtual Screening Opportunities in Drug Discovery in Europe generated revenues of $93.2 million in 2006 and estimates this to reach $228.4 million in 2013
Demonstrating Value Created by In-Silico Solutions to Help Maximise Virtual Screening Opportunities

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/02/14 - Frost & Sullivan finds that Virtual Screening Opportunities in Drug Discovery in Europe generated revenues of $93.2 million in 2006 and estimates this to reach $228.4 million in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Suppliers in the highly competitive and fragmented European virtual screening market face challenges such as limited scientific audience and the lack of common technology standards. Also, despite the high demand for software tools, companies need to develop and introduce the right kind of tools and solutions to broaden their customer base. The key to success will be to demonstrate to customers the value that can be created by proper implementation of in-silico solutions.

Frost & Sullivan (healthcare.frost.com) finds that Virtual Screening Opportunities in Drug Discovery in Europe generated revenues of $93.2 million in 2006 and estimates this to reach $228.4 million in 2013.

Increasing economic pressure on the pharmaceutical industry to develop new drugs in a faster, efficient and more economic way than in the past has led to the emergence of several new methods aimed at a more efficient and rapid lead structure discovery process.

"Recent advances in combinatorial chemistry have made it possible to synthesise large libraries of compounds, and high throughput screening (HTS) provides a considerable reduction of the time needed for the discovery of new molecules possessing biological activity for a certain target," comments Frost & Sullivan Drug Discovery Team Leader Dr. Amarpreet Dhiman. "With experimental efforts to carry out the biological screening of billions of compounds still high, computational techniques and computer-aided drug design approaches have emerged as promising tools in helping researchers decide what to screen and synthesise."

Most pharmaceutical companies now have access to models that seek to predict key properties of the chemical structures that their research teams plan to synthesise. These range from the simple application of the ubiquitous Lipinski's rule of five, to the relatively sophisticated integration and scoring of a range of predictive models. While the rising use of predictive in-silico models is encouraging, much research remains to be performed to demonstrate appropriate confidence in the output of currently developed models and broaden the chemistry space covered.

In the drug development process, the data most readily available is that which concerns efficacy and selectivity. Often, at this point, researchers will transfer the compound to a preclinical stage using animal models, where the data becomes less consistent from study to study.

To create the most accurate predictive models, software developers need to have access to accurate and consistent data, so that they can model interstudy variations and reduce those variations to key characteristics. However, for a number of reasons, information from different laboratories is often not compatible, and thus a reasonable amount of consistent data is needed to build better models.

"Many companies are using in-silico techniques, but there is concern that these models are causing promising compounds to be disregarded based on in-silico model results," adds Dr. Dhiman. "This is resulting is some scepticism and uncertainty in the acceptance of these tools."

Informatics applications for toxicity screening is an area requiring further development and proof of concept studies, as confidence among researchers remains limited. Companies are very sceptical about the reliability of these models compared to actual experimentation. The prediction that in-silico models would replace in vivo and in vitro testing is yet to be fulfilled with current landscape favouring the belief that the best results will occur through a simultaneous use of all available tools.

"To allow companies to reap the benefits from in-silico studies, in the first instance, the data generated needs to be of high quality, reliable and accurate," advises Dr. Dhiman. "A key to achieving this objective would be to develop tools that facilitate data consolidation and information sharing; then systems would be standardised, allowing for solutions that integrate data from numerous tools and experiments."

Moreover, manufacturers should offer their services in data management, training and tool maintenance among others. They should function as both service provider and product developer. By partnering with clinical organisations, informatics and tool companies, manufacturers would be able to create solutions that best meet research needs.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the Virtual Screening Opportunities in Drug Discovery in Europe (M045 - 48), send an e-mail to Radhika Menon Theodore - Corporate Communications at rmtherodore[.]frost.com with your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information through email upon receipt of the above information.

Virtual Screening Opportunities in Drug Discovery in Europe is part of the Drug Discovery and Diagnostic Technologies Subscription, which also includes research in the following markets: Gene Expression Markets in Europe, Contract Research Organisations (CROs) Markets in Europe and Nucleic Acid Isolation Markets in Europe. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

Melina Trevino
Corporate Communications - Americas
P: +1-210-247-2440
F: +1-210-348-1003
E: melina.trevino[.]frost.com

Keywords in this release: virtual screening in drug discovery, virtual screening, drug discovery, market, Europe, software tools, in-silico solutions, pharmaceutical industry, drugs, lead structure discovery process, combinatorial chemistry, high throughput screening, HTS, biological screening, computational techniques, computer-aided drug design, Lipinski's rule of five, predictive in-silico models, drug development, animal models, predictive models, software developers, informatics applications, toxicity screening, proof of concept studies, in vivo, in vitro testing

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Demonstrating Value Created by In-Silico Solutions to Help Maximise Virtual Screening Opportunities

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Radhika Menon Theodore 
+91-44-42044541 rmtherodore[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Frost & Sullivan Recognizes Ventec Life Systems for New Product Innovation - Game-changing, Modular Respiratory System, VOCSN
BD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis
GE Healthcare Advances the Delivery of Cell Therapies with New Thawing Technology
Ansell Limited Announces the Closing of the Sale of its Sexual Wellness Business
PQ Bypass Earns Frost & Sullivan’s European Technology Innovation Award for its Proprietary DETOUR System for Percutaneous Bypass
Curaçao EMS Uses ZOLL Autopulse to Save Tourist in Sudden Cardiac Arrest
ZOLL to Showcase Expanded Portfolio of AEDs at Caravan Salon 2017
MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®
MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test
Datalogic Announces New Healthcare Memor X3 HC Mobile Computer
Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System
SelectMDx to be Distributed Across Middle East by IPS Genomix
GE Healthcare Partners with Oritain to Introduce Independent Test to Confirm Country of Origin of Fetal Bovine Serum
Saebo, Inc. Awarded Patent for Low-Profile Stroke Recovery Glove

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)